Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...
Process and outcome indicators for evaluation of surgical activity in a high-risk gastric cancer area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback